UCB buffs up in block­buster pso­ri­a­sis race as bimek­izum­ab beats Hu­mi­ra in head-to-head

Just weeks af­ter boast­ing head-to-head vic­to­ries over first place­bo and then J&J’s IL-23 con­tender Ste­lara in clear­ing pso­ri­a­sis, the re­sults are in for UCB’s last Phase III tri­al, in which bimek­izum­ab went up against the world’s best-sell­ing drug.

On­ly topline re­sults are pro­vid­ed for to­day’s read­out of the BE SURE study, so we won’t find out just how su­pe­ri­or bimek­izum­ab proved against Hu­mi­ra on the co-pri­ma­ry end­points — stan­dard scores known as PASI90 and IGA mea­sur­ing the im­pact and sever­i­ty of the dis­ease — un­til a sci­en­tif­ic con­fer­ence in 2020.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.